Bone mass has previously been shown to be reduced at peripheral bone sites in patients with bronchial asthma receiving corticosteroids. To assess whether total bone mass is reduced in asthma total body calcium was measured by in vivo neutron activation analysis in patients receiving various treatments for asthma and compared with results from normal controls and patients with rheumatoid arthritis and polymyalgia rheumatica. Compared with controls total body calcium was reduced by 13 6% (p<0-001) in patients with asthma receiving daily oral corticosteroids but by only 9*0% (p<0005) in a similar group of patients who had received oral calcium supplements at the start of their corticosteroid treatment. Total body calcium was also reduced in a group of patients receiving only inhaled corticosteroids (8-8%; p<O-OOl) but not significantly reduced in a small group of patients with asthma who had never received these drugs. When compared with controls a group of patients matched for age and for dose of corticosteroids given for rheumatoid arthritis had a similar reduction in total body calcium to the patients with asthma receiving daily oral treatment (17-7%; p<0-001), but no such reduction was shown in patients with polymyalgia rheumatica. These findings suggest that the risk of bone loss with low dose oral corticosteroids is similar in asthma and rheumatoid arthritis. Further work is required to assess the clinical relevance of small losses of bone associated with the use of inhaled corticosteroids.
Since Cushing's original description of the syndrome in 1932 it has been recognised that supraphysiological concentrations of endogenous corticosteroids are associated with excess bone loss. ' The introduction of cortisone as a therapeutic agent was followed very shortly by case reports of spontaneous fractures during treatment,2 and subsequently radiological osteoporosis was reported at various skeletal sites.'4 The cause of corticosteroid induced osteoporosis is now better understood' but there remains controversy about the dose and duration of treatment with synthetic corticosteroids necessary to induce osteoporosis.6'-Whether or not bone loss can be prevented by altering the route or timing of drug administration' 9 remains uncertain. There is also continuing controversy whether patients with some diseases may be less susceptible. ' As there is a relative paucity ofdata on bone mass in asthmatics we have carried out measurements of total body calcium in groups of patients with bronchial asthma treated with oral and inhaled corticosteroids and compared the results with those in people who have not received steroids. The results were also compared from those from patients with rheumatoid arthritis and polymyalgia rheumatica receiving regular oral corticosteroid treatment and from controls matched for age and sex.
Patients and methods
We measured total body calcium in 70 patients with asthma (28 men, 42 women). The total group was subdivided according to current and previous treatment. Group 1 1) showed a reduction in mean total body calcium in group 1 BRITISH MEDICAL JOURNAL VOLUME 293 6 DECEMBER 1986 (13.6%; p<O0OOl), group 2 (9 0%; p<0005), and group 3 (8.8%; p<0.001).
There was also a significant difference in mean total body calcium between groups 1 and 4 (811%; p<O05). No significant differences were found between men and women.
No correlations were shown between the duration of disease and total body calcium in any of the four groups with asthma nor between the duration of calcium treatment and total body calcium in patients in group Table   II gives details of sex ratio, age, corticosteroid treatment, and total body calcium values in group 1 patients with asthma and patients with rheumatoid arthritis and polymyalgia rheumatica. No significant differences were found between the patient groups with regard to age or corticosteroid treatment except that the patients with asthma had received oral steroids for longer than the patients with rheumatoid arthritis (7 4 years; p<001l) and polymyalgia rheumatica (8-8 years; p<0'0O1).
Comparison of normalised results in these three groups with controls showed a reduction in mean total body calcium in patients with rheumatoid arthritis (17 7%; p<0c001) but none in those with polymyalgia rheumatica (fig 2) . Compared with the group with polymyalgia bone mass was reduced in the patients with asthma (13-2%; p<0102) and rheumatoid arthritis (1733%; p<0-011). The apparent difference in mean total body calcium between the patients with asthma and those with rheumatoid arthritis did not reach statistical significance (0' 1 >p>05)).
The reduction in total body calcium was not related to the duration of treatment or the total steroid dose (daily dose x duration) in any of the groups but was correlated with the mean daily dose of prednisolone in those patients with rheumatoid arthritis (r= 0605; p<001) ).
Discussion
Oral corticosteroid treatment has previously been associated with reduced bone mass in patients with bronchial asthma.80 These BRMSH MEDICAL JOURNAL VOLUME 293 6 DECEMBER 1986 1465 studies compared treated patients with normal controls using different measurements of forearm bone mass. Though unlikely, the possibility that bone mass might be reduced in asthma as a consequence of the disease itself was not considered. As bones contain 990b of the body's calcium contente it is a reasonable assumption that total body calium is a measurement of total bone mass, particularly as it is extremely well correlated with the total bone mineral content of the skeleton measured by dual photon absorptiometry.2" Hence this study confirms that reduced total bone mass does occur in patients with bronchial asthma treated with daily oral corticosteroids (group 1) when compared both with age matched normal controls and with young asthmatics who had never received steroids (group 4). Though this latter group was significantly younger than the controls, other studies have failed to show a relation between total body calcium and age in men or premenopausal women,'4 suggesting that the loss ofbone in group 1 was attributable to steroid treatment rather than to age or disease. The reduction in amen total body calcium of 13-6% in group 1 was substantial. Postmenopausal patients with crush fractures have a mean reduction in total body calcium of 16-200ie,t Despite higher daily doses and a longer duration ofcorticosteroid treatment a small group of patients (group 2) who had received oral calcium supplements at the start of treatment had a slightly greater mean total body calcium than those in group 1 (4-6%; 0 I>p>O05). This suggests that the use oforal calcium supplements alone given at the start of cortcosteroid treatment should be further investigated as a possible means ofpreventing os.teoporosis. Other studies aimed at overcoming the calcium malabsorption known to be associated with corticosteroid treatment25 have shown some benefit with 25-hydroxy vitamin I)" but not wth 1,25-dihydroxy vitai DYD The use of inhaled corticosteroids in asthma is almost cetinly associated with a reduction in systemic side effects compared with oral treatment2' 2 but suppression of the hypothalamic-adrenal axis may occur with large doses.>32 0There is little doubt that the main portion of the aerosol dose is deposited in the mouth and swallowed,33 allowing gastrointestinal as well as pulmonary absorption. The finding that total body calcium was reduced in patients in group 3 by a mean of 8-8% compared with controls is therefore of concern. Sixteen of the 22 patients had received booster courses of oral corticosteroids, and such intermittent treatment has been associated with minor reductions of bone mass in patients with aIma.' The six patients who had never received oral treatment, however, had some of the lowest individual values of total body calcium (fig 1) . T4is suggests that inhaled corticosteroids might be at least in part responsible for the reduction in group 3. The widespread and increasing use of high dose corticosteroid inhalersT4
suggests that further studies of bone mass in patients so treated should be undertaken. The pending development of inhaled corticosteroids which have an improved topical to systemic ratio3335 should be encouraged.
The effects of corticosteroids on bone mass in patients with asthma, rheumatoid arthritis, and polymyalgia rheumatica were compared (fig 2) . Both patients with asthma and those with rheumatoid arthritis had reduced bone mass compared with patients treated for polymyalgia rheumatica but we were unable to confirm previous studies,"'2 including our own preliminary data,'3 which suggested that corticosteroid treated patients with rheumatoid arthritis were more susceptible to bone loss than patients with asthma treated with similar daily doses. This study shows a small reduction in mean total body calcium (4 3%) in steroid treated patients with rheumatoid arthritis compared with asthmatics. As we have previously shown that total body calcium is reduced by 50-6-8% in patients with rheumatoid arthritis who have never received corticosteroids,'5 this reduction in bone mass may be attributable to the effects ofthe disease process, which causes appreciable bone loss at peripheral sites. m Total body calcium is inversely related to the daily dose of prednisolone in patients with rheumatoid arthritis (r=-0 605; p<O0OO1). This finding raised the hypothesis that corticosteroid induced bone loss might occur early in the course oftreatment,'5 and a recent longitudinal study has lent support to this theory. Lack of a similar relation between total body calcium and daily steroid dose in asthma may reflect the wider fluctuations in individual steroid doses in these patients.
The explanation for the normal bone mass in patients with polymyalgia rheumatica is not clear. Women with polymyalgia rheumatica were older than those in the two other groups and the magnitude of the corticosteroid induced bone loss may not be apparent because of the substantial yearly 1-5% correction after the '4 mepopause.
At preset there is little convincing evidnce for increased or decreased susceptibility to corticosteroid induced bone loss in patents with asthma or rheumatoid arthritis, though the position in patients with polymyalga rheutica may require further studies including larger numbers of subjects. The effects of these changes on alcohol related problems in Scotland have recently been examined. 2 No increase in death rates from cirrhosis and alcoholism was found compared with England and Wales. There was a fall in the incidence ofpublic order offences related to alcohol since the law was changed in 1976. A lag phaie, however, would be expected before the death rate from cirrhosis began to rise, and numbers of deaths from alcoholism are very small. Convictions for public order offences may reflect policing policies as much as alcohol consumption. These deficiencies have been highlighted and recommendations made to consider data which reflect alcohol consumption in the community more accurately. 3 This study emines the frequency of alcohol intake associated with admissions for selfpoisoning during the six year periods before and after the change in the law and the effects of alcohol on the medical outcome of these episodes.
Present study and results
Milesmark Hospital serves a mixed urban and rural population ofroughly
